Literature DB >> 12507094

The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review.

Marc Levivier1, David Wikler, Nicolas Massager, Philippe David, Daniel Devriendt, Jose Lorenzoni, Benoit Pirotte, Françoise Desmedt, Stephane Simon, Serge Goldman, Paul Van Houtte, Jacques Brotchi.   

Abstract

OBJECT: The authors review their experience with the clinical development and routine use of positron emission tomography (PET) during stereotactic procedures, including the use of PET-guided gamma knife radiosurgery (GKS).
METHODS: Techniques have been developed for the routine use of stereotactic PET, and accumulated experience using PET-guided stereotactic procedures over the past 10 years includes more than 150 stereotactic biopsies, 43 neuronavigation procedures, and 34 cases treated with GKS. Positron emission tomography-guided GKS was performed in 24 patients with primary brain tumors (four pilocytic astrocytomas, five low-grade astrocytomas or oligodendrogliomas, seven anaplastic astrocytomas or ependymomas, five glioblastomas, and three neurocytomas), five patients with metastases (single or multiple lesions), and five patients with pituitary adenomas.
CONCLUSIONS: Data obtained with PET scanning can be integrated with GKS treatment planning, enabling access to metabolic information with high spatial accuracy. Positron emission tomography data can be successfully combined with magnetic resonance imaging data to provide specific information for defining the target volume for the radiosurgical treatment in patients with recurrent brain tumors, such as glioma, metastasis, and pituitary adenoma. This approach is particularly useful for optimizing target selection for infiltrating or ill-defined brain lesions. The use of PET scanning contributed data in 31 cases (93%) and information that was specifically utilized to adapt the target volume in 25 cases (74%). It would seem that the integration of PET data into GKS treatment planning may represent an important step toward further developments in radiosurgery: this approach provides additional information that may open new perspectives for the optimization of the treatment of brain tumors.

Entities:  

Mesh:

Year:  2002        PMID: 12507094     DOI: 10.3171/jns.2002.97.supplement

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

1.  [Preoperative imaging as the basis for image-guided neurosurgery].

Authors:  D Winkler; G Strauss; S Hesse; A Goldammer; M Hund-Georgiadis; A Richter; O Sabri; T Kahn; J Meixensberger
Journal:  Radiologe       Date:  2004-07       Impact factor: 0.635

2.  [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.

Authors:  S Ceyssens; K Van Laere; T de Groot; J Goffin; G Bormans; L Mortelmans
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

Review 3.  Stereotactic radiosurgery and interstitial brachytherapy for glial neoplasms.

Authors:  M W McDermott; M S Berger; Sandeep Kunwar; Andrew T Parsa; P K Sneed; David A Larson
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

4.  Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.

Authors:  Bich-Ngoc-Thanh Tang; Niloufar Sadeghi; Fabrice Branle; Olivier De Witte; David Wikler; Serge Goldman
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

5.  Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study.

Authors:  K Miwa; J Shinoda; H Yano; A Okumura; T Iwama; T Nakashima; N Sakai
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

6.  Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.

Authors:  Koen Van Laere; Sarah Ceyssens; Frank Van Calenbergh; Tjibbe de Groot; Johan Menten; Patrick Flamen; Guy Bormans; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

7.  The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II.

Authors:  Anja Smits; Brigitta G Baumert
Journal:  Int J Mol Imaging       Date:  2011-04-28

8.  Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.

Authors:  C Walker; B Haylock; D Husband; K A Joyce; D Fildes; M D Jenkinson; T Smith; J Broome; K Kopitzki; D G du Plessis; J Prosser; S Vinjamuri; P C Warnke
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

9.  Integration of Three-dimensional Magnetic Resonance Imaging Spectroscopy with the Leksell GammaPlan Radiosurgical Planning Station for the Treatment of Brain Tumors.

Authors:  Fahd Derkaoui Hassani; Adyl Melhaoui; Younes Dif; Abdelhanine Oumoussa; Mohammed Jiddane; Yasser Arkha; Abdeslam El Khamlichi
Journal:  Cureus       Date:  2019-10-20

10.  [11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme.

Authors:  Christian Pötzi; Alexander Becherer; Christine Marosi; Georgios Karanikas; Monika Szabo; Robert Dudczak; Kurt Kletter; Susanne Asenbaum
Journal:  J Neurooncol       Date:  2007-05-11       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.